0000000000559106

AUTHOR

Maria Pia Foschini

0000-0001-7079-7260

showing 3 related works from this author

Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population

2010

BackgroundAlbeit several studies pointed out the pivotal role that CD4+T cells have in Multiple Sclerosis, the CD8+ T cells involvement in the pathology is still in its early phases of investigation. Proteasome degradation is the key step in the production of MHC class I-restricted epitopes and therefore its activity could be an important element in the activation and regulation of autoreactive CD8+ T cells in Multiple Sclerosis.Methodology/principal findingsImmunoproteasomes and PA28-alphabeta regulator are present in MS affected brain area and accumulated in plaques. They are expressed in cell types supposed to be involved in MS development such as neurons, endothelial cells, oligodendroc…

MaleT cells proteasomes multiple sclerosis parietal lobeMuscle ProteinsImmunoproteasomeEpitopeEpitopesGene FrequencyRisk FactorsCytotoxic T cellFunding: This work was financed in part by the grant Giovani Ricercatori 2007 from Italian Ministry of Health to MM DG and FMB by a grant from the European Commission Integrated Project PROTEOMAGE (FP6) to CF by the finalized projects of Fondazione Italiana Sclerosi Multipla (FISM) cod. 2003/R26 and BioPharmaNet to CF and 2002/R/40 and 2005/R/10 2008/R/11 (Genoa) to SD'A by the University of Bologna (FRO) to MPF by the Regione Piemonte (Ricerca Sanitaria Finalizzata Project and Ricerca Sanitaria Applicata-CIPE Project) to SD'A by Associazione Amici del Centro Dino Ferrari and IRCCS Ospedale Maggiore Policlinico Milano to DG and by the grants Sonderforschungsbereich (SFB-507 SFB-421) to PMK and US the grants TR43 and Neurocure to PMK. MM benefited from the A.V. Humboldt PostDoc fellowship. The funders had no role in study design data collection and analysis decision to publish or preparation of the manuscript.MultidisciplinaryMicrogliaQRBrainMiddle AgedImmunohistochemistryCysteine EndopeptidasesOligodendrogliamedicine.anatomical_structureItalyImmunoproteasome; multiple sclerosis; italian populationmultiple sclerosiImmunology/Antigen Processing and RecognitionMedicineFemaleMicrogliaNeuroscience/Neurobiology of Disease and RegenerationResearch ArticleProtein BindingAdultProteasome Endopeptidase ComplexMultiple SclerosisGenotypeScienceMolecular Sequence DataImmunology/AutoimmunityBiologySex FactorsMHC class IHLA-A2 AntigenmedicineHumansAmino Acid SequenceAlleleHLA-A AntigensMultiple sclerosisMacrophagesMyelin Basic Proteinmedicine.diseaseMyelin basic proteinImmunologybiology.proteinitalian populationCD8PLoS ONE
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

Clinical validation of 13-gene DNA methylation analysis in oral brushing samples for detection of oral carcinoma: an Italian multicenter study

2021

Background The aim of this Italian multicenter study was to evaluate the diagnostic performance of a minimally invasive method for the detection of oral squamous cell carcinoma (OSCC) based on 13-gene DNA methylation analysis in oral brushing samples. Methods Oral brushing specimens were collected in 11 oral medicine centers across Italy. Twenty brushing specimens were collected by each center, 10 from patients with OSCC, and 10 from healthy volunteers. DNA methylation analysis was performed in blindness, and each sample was determined as positive or negative based on a predefined cutoff value. Results DNA amplification failed in 4 of 220 (1.8%) samples. Of the specimens derived from patien…

0301 basic medicinemedicine.medical_specialtyBisulfite sequencingalgorithm; bisulfite sequencing; diagnostic test; oral brushing; oral squamous cell carcinoma; quantitative DNA methylation analysisGastroenterologyoral brushing03 medical and health sciences0302 clinical medicineInternal medicineHealthy volunteersCarcinomamedicineHumansquantitative DNA methylation analysisMouth neoplasmalgorithmbusiness.industryDNA Methylationmedicine.diseaseDna amplificationoral squamous cell carcinomastomatognathic diseases030104 developmental biologyItalyOtorhinolaryngologyMulticenter studyHead and Neck Neoplasmsdiagnostic test030220 oncology & carcinogenesisDNA methylationCarcinoma Squamous Cellbisulfite sequencingMouth NeoplasmsbusinessOral medicine
researchProduct